PREVENZIONE DELL'EPATITE B NEGLI EMODIALIZZATI CRONICI MEDIANTE VACCINO RICOMBINANTE: STUDIO PROSPETTICO CON USO DI PROTOCOLLO RINFORZATO

Translated title of the contribution: Prevention of hepatitis B infection in chronic hemodialysis (HD) patients with recombinant vaccine: A prospective study with reinforced schedule

F. Fabrizi, G. Bacchini, S. Di Filippo, D. Marcelli, L. Raffaele, I. Guarnori, G. Erba, F. Locatelli

Research output: Contribution to journalArticlepeer-review

Abstract

The prevalence of HBsAg chronic carriers in our unit was 4.7%; it was partially related to the length of time on HD. The prevalence of previous HBV infection (40%) was not related to any of the examined factors. Recombinant hepatitis B vaccine was given to 118 chronic HD subjects with a regimen vaccination of 3-40-μg doses administered intramuscularly at 0.1 and 2 months, obtaining an immunization rate of 67% (79/118), 44/79 (56%) being high-responders. Furthermore, at month 12, 87.5% (63/72) of the responder patients maintained protective levels of anti-HBs, 48% (30/63 of them being high-responders). We found significant difference with regard to diabetes mellitus between responder and non-responder groups; serological positivity for antibodies against B core antigen facilitates the fall of anti-HBs antibodies over time.

Translated title of the contributionPrevention of hepatitis B infection in chronic hemodialysis (HD) patients with recombinant vaccine: A prospective study with reinforced schedule
Original languageItalian
Pages (from-to)53-60
Number of pages8
JournalGiornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
Volume11
Issue number1
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Prevention of hepatitis B infection in chronic hemodialysis (HD) patients with recombinant vaccine: A prospective study with reinforced schedule'. Together they form a unique fingerprint.

Cite this